Distinguished in B-Cell Lymphoma

Andrew K. Mcmillan

Nottingham, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in B-Cell Lymphoma
Nottingham, ENG, GB 
OverviewLocationsClinical Research

Overview

Andrew Mcmillan practices in Nottingham, United Kingdom. Mr. Mcmillan is rated as a Distinguished expert by MediFind in the treatment of B-Cell Lymphoma. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 77 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 26 articles in the study of B-Cell Lymphoma.

Gender
Male

Locations

Nottingham, ENG, United Kingdom
Other Locations
London, ENG, United Kingdom
University Rd, Heslington, York, ENG YO105DD, United Kingdom
Bristol, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
Enrollment Status: Recruiting
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Doxorubicin, Vincristine, Dexamethasone, Inotuzumab, Imatinib, 6-Tioguanine, Blinatumomab
Study Phase: Phase 3
Purine-Alkylator Combination In Follicular Lymphoma Immuno-Chemotherapy for Older Patients: a Phase III Comparison of First-line R-CVP Versus R-FC
Purine-Alkylator Combination In Follicular Lymphoma Immuno-Chemotherapy for Older Patients: a Phase III Comparison of First-line R-CVP Versus R-FC
Enrollment Status: Completed
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Cyclophosphamide, Vincristine, Prednisolone, Fludarabine
Study Phase: Phase 3
View 1 Less Clinical Trial

77 Total Publications

The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study.
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study.
Journal: The Lancet. Oncology
Published: July 18, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mcmillan's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile